Landos Biopharma, Inc. (LABP)
Market Cap | n/a |
Revenue (ttm) | n/a |
Net Income (ttm) | -22.31M |
Shares Out | n/a |
EPS (ttm) | n/a |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Dividend Yield | n/a |
Trading Day | n/a |
Last Price | n/a |
Previous Close | n/a |
Change ($) | n/a |
Change (%) | n/a |
Day's Open | n/a |
Day's Range | n/a |
Day's Volume | n/a |
52-Week Range | n/a |
News
Landos Biopharma, a Phase 2 biotech developing oral small molecule therapies for autoimmune diseases, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering.
Landos Biopharma, Inc. has filed to go public with an IPO on the NASDAQ.
About LABP
Landos Biopharma is a clinical-stage biopharmaceutical company developing novel, disease-specific oral therapeutic candidates designed to address the therapeutic gap in the current treatment paradigm for autoimmune diseases.. We believe the therapeutics we discover and develop, if approved, will have a significant impact on the quality of life of patients suffering from autoimmune diseases. While great strides have been made, existing approaches continue to leave patient needs unmet, due in part to significant safety concerns. Our core experti... [Read more...]
Industry Pharmaceutical Preparations | IPO Date Pending |
CEO Josep Bassaganya-Riera | Employees 33 |
Stock Exchange NASDAQ | Ticker Symbol LABP |